These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 10607848)

  • 1. Angiogenesis research: from laboratory to clinic.
    Folkman J
    Forum (Genova); 1999; 9(3 Suppl 3):59-62. PubMed ID: 10607848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of angiogenesis in solid tumours: an overview.
    Makrilia N; Lappa T; Xyla V; Nikolaidis I; Syrigos K
    Eur J Intern Med; 2009 Nov; 20(7):663-71. PubMed ID: 19818284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis research: guidelines for translation to clinical application.
    Folkman J; Browder T; Palmblad J
    Thromb Haemost; 2001 Jul; 86(1):23-33. PubMed ID: 11487011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are tumours angiogenesis-dependent?
    Verheul HM; Voest EE; Schlingemann RO
    J Pathol; 2004 Jan; 202(1):5-13. PubMed ID: 14694516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-angiogenic strategies for cancer therapy (Review).
    Benouchan M; Colombo BM
    Int J Oncol; 2005 Aug; 27(2):563-71. PubMed ID: 16010440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer immunotherapy of targeting angiogenesis.
    Hou J; Tian L; Wei Y
    Cell Mol Immunol; 2004 Jun; 1(3):161-6. PubMed ID: 16219162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour vascular targeting.
    Neri D; Bicknell R
    Nat Rev Cancer; 2005 Jun; 5(6):436-46. PubMed ID: 15928674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
    Hess C; Vuong V; Hegyi I; Riesterer O; Wood J; Fabbro D; Glanzmann C; Bodis S; Pruschy M
    Br J Cancer; 2001 Dec; 85(12):2010-6. PubMed ID: 11747347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A new treatment protocol targeting tumor vasculature--- metronomic chemotherapy combined radiotherapy].
    Qiu H; Wang GM
    Ai Zheng; 2007 Dec; 26(12):1392-6. PubMed ID: 18076810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-molecular-weight heparins and angiogenesis.
    Norrby K
    APMIS; 2006 Feb; 114(2):79-102. PubMed ID: 16519745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination of antiangiogenic therapy with other modalities.
    O'Reilly MS
    Cancer J; 2002; 8 Suppl 1():S89-99. PubMed ID: 12075706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenous angiogenesis inhibitors.
    Folkman J
    APMIS; 2004; 112(7-8):496-507. PubMed ID: 15563312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Angiogenesis and radiotherapy (vessels, anaemia, oxygen and radiosensitivity)].
    Lartigau E
    Bull Cancer; 2007 Jul; 94 Spec No():S197-202. PubMed ID: 17846005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of angiogenesis and the angiogenesis/invasion shift.
    Bikfalvi A; Moenner M; Javerzat S; North S; Hagedorn M
    Biochem Soc Trans; 2011 Dec; 39(6):1560-4. PubMed ID: 22103487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lattice and non-lattice models of tumour angiogenesis.
    Plank MJ; Sleeman BD
    Bull Math Biol; 2004 Nov; 66(6):1785-819. PubMed ID: 15522355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenics and radiotherapy.
    Shannon AM; Williams KJ
    J Pharm Pharmacol; 2008 Aug; 60(8):1029-36. PubMed ID: 18644195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-angiogenic gene therapy of cancer: current status and future prospects.
    Persano L; Crescenzi M; Indraccolo S
    Mol Aspects Med; 2007 Feb; 28(1):87-114. PubMed ID: 17306361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.